Abstract

This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of erlotinib for the treatment of relapsed non-small cell lung cancer (NSCLC), according to its licensed indication, based upon the evidence submission from Roche Products to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submitted clinical evidence includes one randomised controlled trial (RCT) (BR21) investigating the effect of erlotinib versus placebo, which demonstrates that erlotinib significantly increases median overall survival, progression-free survival and response rate compared with placebo. The majority of patients in the trial experienced non-haematological drug-related adverse effects. Currently there are no trials that directly compare erlotinib with any other second-line chemotherapy agent. For the purposes of indirect comparison, the manufacturer’s submission provides a narrative discussion of data from 11 RCTs investigating the use of docetaxel. From these data the manufacturer concludes that erlotinib has similar clinical efficacy levels to docetaxel but results in fewer serious haematological adverse events; however, it is difficult to compare the results of BR21 with those of the docetaxel trials or with current UK clinical practice because, for example, the BR21 patient population is younger than that expected to present in UK clinical practice and almost half of the BR21 participants received erlotinib as third-

Erlotinib for the treatment of relapsed non-small cell lung cancer

C McLeod, A Bagust, A Boland, J Hockenhull, Y Dundar, C Proudlsvpe, H Davis, J Green, F Macbeth, J Stevenson, T Walley and R Dickson*

Liverpool Reviews and Implementation Group (LRiG), Room B05, Whelan Building, The Quadrangle, Brownlow Hill, University of Liverpool, Liverpool, UK

*Corresponding author

Declared competing interests of authors: none. Professor Tom Walley is Editor-in-Chief of Health Technology Assessment, although he was not involved in the editorial process for this supplement.
line chemotherapy, with third-line chemotherapy being rare in the UK. The manufacturer’s submission included a three-state model comparing erlotinib with docetaxel, reporting an incremental cost-effectiveness ratio (ICER) of £1764 per quality-adjusted life-year (QALY) gained for erlotinib compared with docetaxel. Rerunning the manufacturer’s economic model with varied parameters and assumptions increases the ICER to in excess of £52,000 per QALY gained. There is still a large amount of unquantifiable uncertainty in the model and it is unlikely that erlotinib could be considered to be cost-effective compared with docetaxel at a willingness to pay of £30,000 and there may even be the potential for docetaxel to dominate erlotinib. Because of the limitations of the indirect analysis undertaken by the manufacturer and the subsequent economic modelling exercise there is a need for a head-to-head trial comparing erlotinib with docetaxel. The guidance issued by NICE in February 2007 as a result of the STA states that erlotinib is not recommended for the treatment of locally advanced or metastatic NSCLC.

Introduction

The National Institute for Health and Clinical Excellence (NICE) is an independent organisation within the NHS that is responsible for providing national guidance on the treatment and care of people using the NHS in England and Wales. One of responsibilities of NICE is to provide guidance to the NHS on the use of selected new and established health technologies, based on an appraisal of those technologies.

NICE’s single technology appraisal (STA) process is specifically designed for the appraisal of a single product, device or other technology, with a single indication, for which most of the relevant evidence lies with one manufacturer or sponsor. Typically, it is used for new pharmaceutical products close to launch. The principal evidence for an STA is derived from a submission by the manufacturer/sponsor of the technology. In addition, a report reviewing the evidence submission is submitted by the evidence review group (ERG), an external organisation independent of NICE. This paper presents a summary of the ERG report for the STA of erlotinib for the treatment of relapsed non-small cell lung cancer (NSCLC).

Description of the underlying health problem

Lung cancer is the most common cause of cancer-related death in men and the second most common cause of cancer-related death after breast cancer in women. In 2002, 37,700 patients were newly diagnosed with lung cancer in the UK, accounting for one in seven new cancer cases, with an incidence of about 62–65 per 100,000 population; the incidence of NSCLC is approximately 52 per 100,000 population. Lung cancer is rarely diagnosed in people under 40 years of age, but the incidence rises steeply with age thereafter, peaking in people aged 75–84 years. The male–female ratio for lung cancer cases is 3:2. There is a strong association between incidence and mortality rates and levels of deprivation.

Scope of the ERG report

The ERG report presents the results of the assessment of the manufacturer’s (Roche Products) evidence submission regarding the use of erlotinib for the second-line treatment of patients with locally advanced or metastatic (stage III/IV) NSCLC. The report includes an assessment of both the clinical and cost-effectiveness evidence submitted by the manufacturer. Erlotinib (Tarceva®) is an orally active inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) tyrosine kinase inhibitor. In 2004, pemetrexed (Alimta®; Lilly) received a licence for use ‘as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy’. The licensing submission for pemetrexed was supported by a phase III study comparing pemetrexed and docetaxel. In 2005, erlotinib was licensed ‘for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen’. The licensing submission for erlotinib was supported by a phase III study comparing erlotinib with placebo.

Methods

The ERG report comprised a critical review of the evidence for the clinical effectiveness and cost-effectiveness of the technology based upon the manufacturer’s/sponsor’s submission to NICE.
as part of the STA process. The ERG assessed
the quality of the clinical effectiveness review
using a checklist and conducted a literature
search. The group fitted exponential curves
to the manufacturer’s Kaplan–Meier plots to
calculate overall survival (OS) and also reran the
manufacturer’s economic model after correcting
for an inherent error and altered some of the
assumptions and parameter values to recalculate
the cost–utility ratios, quality-adjusted life-years
(QALYs) and estimates of benefits.

Results

Summary of submitted clinical evidence

The submitted clinical evidence includes one
randomised, placebo-controlled, double-blind trial
(BR21) that investigates the effect of erlotinib
within its licensed indication (treatment of
relapsed NSCLC) versus placebo. The BR21 trial
demonstrates that erlotinib significantly increases
median OS by 42.5% compared with placebo (6.7
months versus 4.7 months respectively; \( p < 0.001 \),
hazard ratio 0.70). Progression-free survival (PFS) is
significantly longer in the erlotinib arm compared
with the placebo arm (2.2 months versus 1.8
months respectively; \( p < 0.001 \), hazard ratio 0.61)
and the overall response rate is significantly higher
(8.9% versus 0.9%; \( p < 0.001 \)).

The majority of patients in the BR21 trial
experienced non-haematological drug-related
adverse effects (AEs). The most commonly reported
AEs attributed to erlotinib were rash (76%) and
diarrhoea (55%), leading to a dose reduction in
12% and 5% of patients respectively. Currently
there are no trials that directly compare erlotinib
with any other second-line chemotherapy agent.
For purposes of indirect comparison, the
manufacturer’s submission provides a narrative
discussion of data from 11 randomised controlled
trials (RCTs) investigating the use of docetaxel at
a dose of 75 mg/m². The manufacturer extracted
detailed data from two of the 11 trials involving
docetaxel: docetaxel versus best supportive care
(TAX317) and docetaxel versus pemetrexed
(JMEI). In these trials docetaxel showed similar
efficacy levels to those of erlotinib as reported
in the BR21 trial. Median OS was 7.5 months
docetaxel, TAX317), 7.9 months (docetaxel, JMEI)
and 6.7 months (erlotinib, BR21). Median PFS was
reported as 2.9 months (docetaxel, JMEI) and 2.2
months (erlotinib, BR21) and overall response rates
were reported as 8.9% (docetaxel, JMEI) and 8.8%
erlotinib, BR21). Analyses of TAX317 and JMEI in

relation to the BR21 study demonstrated the lower
rates of haematological toxicities experienced
by patients receiving erlotinib compared with
those receiving docetaxel, particularly incidences
of febrile neutropenia. The manufacturer’s
submission therefore concludes that erlotinib has
similar clinical efficacy levels to docetaxel but
results in fewer serious haematological adverse
events. When interpreting the results of BR21 a
number of issues relating to the patient population
must be considered. For example, the BR21
patient population is younger than that expected
to present in UK clinical practice. Almost half of
the trial participants received erlotinib as third-
line chemotherapy, with third-line chemotherapy
being rare in the UK. Furthermore, a large number
of participants in the BR21 trial had an Eastern
Cooperative Oncology Group performance status
(ECOG PS) of 2–3; typically patients receiving
chemotherapy in UK clinical practice have a PS of
0–1. For these reasons it is difficult to compare the
results of BR21 with those of TAX317 and JMEI or
with current UK clinical practice.

Summary of submitted cost-
effectiveness evidence

The economic model submitted in support of
the manufacturer’s submission is a basic three-
state model comparing erlotinib with docetaxel,
furnished with clinical data from the TAX317
and BR21 trials. The manufacturer reports an
incremental cost-effectiveness ratio (ICER) of
£2941 per QALY for erlotinib compared with
docetaxel, with a 68% probability that erlotinib
is cost-effective at a willingness to pay (WTP) of
£30,000 per QALY gained. After adjustment for
the double counting of half-cycle correction, the
manufacturer’s model yields a corrected ICER of
£1764. However, a number of key assumptions
and parameters in the model do not seem to be
clinically and/or economically justified, particularly
in terms of costs. For example, the manufacturer
underestimates the acquisition cost of erlotinib
and overestimates the acquisition cost of docetaxel.
Once these assumptions are adjusted to reflect
more realistic estimates, the ICER increases to
£52,098 per QALY as shown in Table 1, with a 44%
probability that erlotinib is cost effective at a WTP
of £30,000. A modified cost-acceptability curve
using manufacturer probabilistic sensitivity analysis
(PSA) results adjusted for average incremental
cost and outcome alterations and a modified
cost-effectiveness uncertainty scatter plot using
manufacturer PSA results adjusted for average
incremental cost and outcome alterations are shown in Figures 1 and 2 respectively.
TABLE 1 Cost-effectiveness summary table updated for identified corrections and amendments to the manufacturer’s model

<table>
<thead>
<tr>
<th>Costs per patient</th>
<th>Erlotinib</th>
<th>Docetaxel</th>
<th>Increment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug acquisition</td>
<td>£7164</td>
<td>£5022</td>
<td>£2142</td>
</tr>
<tr>
<td>Drug administration and monitoring</td>
<td>£473</td>
<td>£839</td>
<td>£365</td>
</tr>
<tr>
<td>Adverse event treatment</td>
<td>£113</td>
<td>£374</td>
<td>£261</td>
</tr>
<tr>
<td>Other preprogression care</td>
<td>£1034</td>
<td>£859</td>
<td>£175</td>
</tr>
<tr>
<td>Postprogression care</td>
<td>£4699</td>
<td>£5444</td>
<td>£745</td>
</tr>
<tr>
<td>Total cost</td>
<td>£13,482</td>
<td>£12,536</td>
<td>£946</td>
</tr>
</tbody>
</table>

Outcomes per patient

<table>
<thead>
<tr>
<th>Overall mean survival (months)</th>
<th>9.03</th>
<th>9.03</th>
<th>0.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS (months)</td>
<td>4.11</td>
<td>3.33</td>
<td>0.78</td>
</tr>
<tr>
<td>PPS (months)</td>
<td>4.92</td>
<td>5.70</td>
<td>0.78</td>
</tr>
<tr>
<td>PFS QALYs</td>
<td>0.1591</td>
<td>0.1139</td>
<td>0.0452</td>
</tr>
<tr>
<td>PPS QALYs</td>
<td>0.0953</td>
<td>0.1224</td>
<td>0.0271</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>0.2544</td>
<td>0.2362</td>
<td>0.0182</td>
</tr>
</tbody>
</table>

Incremental cost per QALY £52,098

PFS, progression-free survival; PPS, post-progression survival; QALY(s), quality-adjusted life-year(s).

In terms of health outcomes a further issue is the use of visual analogue scale (VAS) scores from the Oxford Outcomes study; the scores were not adjusted to zero for death and conflict with the tariff values calculated using responses from the same sample of healthy volunteers. As presented in Table 2, reanalysis of the model rescaling the VAS PFS utility scores to ensure that death has zero utility further increased the ICER (£68,673 per QALY gained). Similarly, reanalysis using tariff PFS utility values led to an ICER slightly above the WTP threshold of £30,000 (£31,261 per QALY gained). Joint exploration of uncertainty in the cost of docetaxel and the degree of variation in dosing introduced by clinical judgement yields a range of ICER estimates between £41,943 and £70,418 per QALY gained.

There is also a large amount of unquantifiable uncertainty in the model relating to AEs, postprogression survival and PFS health state costs, and the length of PFS. These areas of ambiguity
FIGURE 2 Modified cost-effectiveness uncertainty scatter plot using manufacturer probabilistic sensitivity analyses results adjusted for average incremental cost and outcome alterations. QALY(s), quality-adjusted life-year(s).

TABLE 2 Sensitivity analyses – alternative methods to estimate utility in preprogression period

<table>
<thead>
<tr>
<th></th>
<th>Erlotinib</th>
<th>Docetaxel</th>
<th>Increment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Using rescaled VAS values in PFS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFS QALYs (rescaled VAS)</td>
<td>0.1292</td>
<td>0.0883</td>
<td>0.0409</td>
</tr>
<tr>
<td>PPS QALYs (the ERG estimate)</td>
<td>0.0953</td>
<td>0.1224</td>
<td>−0.0271</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>0.2245</td>
<td>0.2107</td>
<td>0.0138</td>
</tr>
<tr>
<td>Incremental cost per QALY</td>
<td></td>
<td></td>
<td>£68,673</td>
</tr>
<tr>
<td>Using tariff values in PFS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFS QALYs (tariff)</td>
<td>0.1337</td>
<td>0.0763</td>
<td>0.0573</td>
</tr>
<tr>
<td>PPS QALYs (the ERG estimate)</td>
<td>0.0953</td>
<td>0.1224</td>
<td>−0.0271</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>0.2289</td>
<td>0.1987</td>
<td>0.0303</td>
</tr>
<tr>
<td>Incremental cost per QALY</td>
<td></td>
<td></td>
<td>£31,261</td>
</tr>
</tbody>
</table>

ERG, evidence review group; PFS, progression-free survival; PPS, post-progression survival; QALY(s), quality-adjusted life-year(s); VAS, visual analogue scale.

could potentially further increase the ICER and may even result in docetaxel dominating erlotinib.

Commentary on the robustness of submitted evidence

A major limitation in the manufacturer’s submission is the reliance on the BR21 trial (currently the only available erlotinib study) which compares erlotinib with placebo, rather than an accepted chemotherapy regimen. As a consequence, the manufacturer’s submission is forced to compare erlotinib and docetaxel indirectly; such comparisons have inherent difficulties and are subject to biases.

Further to this, there are a number of differences between the patient population in the BR21 trial and the TAX317 study, of which the most important are the number of prior chemotherapy regimens and the performance status of patients.
TABLE 3  Main elements of monthly postprogression costs per patient

<table>
<thead>
<tr>
<th>Component</th>
<th>Cost per month</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital episodes</td>
<td>£547.97</td>
<td>55.4%</td>
</tr>
<tr>
<td>Health professionals</td>
<td>£331.54</td>
<td>33.5%</td>
</tr>
<tr>
<td>Medications</td>
<td>£39.46</td>
<td>4.0%</td>
</tr>
<tr>
<td>Tests</td>
<td>£69.83</td>
<td>7.1%</td>
</tr>
<tr>
<td>Total</td>
<td>£988.80</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

In addition, the best supportive care component of treatment may not be comparable between the trials, which could potentially inflate a treatment response in one of the trials unjustifiably. This confounding issue was not discussed in the manufacturer’s submission, but should have been considered when the indirect comparison was undertaken.

A number of unquantifiable areas of uncertainty were found and relate to AEs, pre- and post-progression health state costs and progression-free survival. There is a note in the manufacturer’s table of event probabilities for AEs, which seems to imply that the model does not allow patients to suffer multiple adverse events. If this is so it is a severe and unrealistic constraint, as individual patients frequently suffer multiple events either concurrently (e.g. rash with diarrhoea) or serially. In addition, the resources assumed to be incurred each month for patients before and after disease progression were exclusively determined by five clinical experts without use of any observational data. The main elements contributing to the increase in such costs postprogression are shown in Table 3. Clearly hospital episodes constitute the dominant component in these estimates. It seems disappointing that no attempt has been made to sample routine hospital records and statistics to validate the expert opinion in this respect. The ERG raised issues about the validity of the claims of equivalence in overall survival and of improved PFS with erlotinib. These are of profound importance to the economic evaluation of erlotinib as if either of these assertions proves to be untenable then most of the modest outcome gains claimed for erlotinib will disappear, other than the very small short-term quality of life benefits associated with oral administration and reduced AEs. In the context of important increases in drug acquisition costs this would mean that erlotinib could not be considered cost-effective and might in fact be dominated by docetaxel (more expensive and less effective).

Conclusions

The manufacturer’s submission presents a case for the replacement of docetaxel by erlotinib as second-line chemotherapy for NSCLC patients with advanced or metastatic disease. However, there is a proportion of NSCLC patients whose poor health status precludes them from receiving docetaxel; for these patients best supportive care is currently the only treatment option available. It may be argued that some of these patients could be considered for erlotinib instead of docetaxel as it is a less demanding oral regimen.

The ERG attempted to rectify several of the limitations in the clinical and cost-effectiveness evidence submitted, generating much higher incremental cost-effectiveness ratios than those generated in the manufacturer’s submission (in excess of £52,000). This extreme sensitivity is due to the very small value of incremental benefit, which renders the ICER highly unstable to small changes. There is still a large amount of unquantifiable uncertainty, however at the current price it is unlikely that erlotinib could be considered to be cost effective compared with docetaxel at a WTP of £30,000. There may even be the potential for docetaxel to dominate erlotinib (i.e. be more effective yet less expensive). This means that adoption of erlotinib would need to be justified on grounds out with the factors included in the model (for example, patient preference for oral self-medication and service pressures to limit or reduce demand for hospital administered chemotherapy).

Given the limitations of the indirect analysis undertaken by the manufacturer and the subsequent economic modelling exercise there is a need for a head-to-head trial comparing erlotinib with docetaxel.
Summary of NICE guidance issued as a result of the STA

The guidance issued by NICE in February 2007 states that:

1.1 Erlotinib is recommended, within its licensed indication, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) only on the basis that it is provided by the manufacturer at an overall treatment cost (including administration, adverse events and monitoring costs) equal to that of docetaxel.

1.2 The decision to use erlotinib or docetaxel (as outlined in section 1.1) should be made after a discussion between the responsible clinician and the individual about the potential benefits and adverse effects of each treatment.

1.3 Erlotinib is not recommended for the second-line treatment of locally advanced or metastatic NSCLC in patients for whom docetaxel is unsuitable (that is, where there is intolerance of or contraindications to docetaxel) or for third-line treatment after docetaxel therapy.

1.4 People currently receiving treatment with erlotinib, but for whom treatment would not be recommended according to section 1.3, should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Key references


